[Treatment of herpes zoster with cytarabine]. 1976

V M de Moraes, and V A Neto, and J Pasternak, and G W Oselka, and G C Levi

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001835 Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms. Body Weights,Weight, Body,Weights, Body
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003561 Cytarabine A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) Ara-C,Arabinofuranosylcytosine,Arabinosylcytosine,Cytosine Arabinoside,Aracytidine,Aracytine,Cytarabine Hydrochloride,Cytonal,Cytosar,Cytosar-U,beta-Ara C,Ara C,Arabinoside, Cytosine,Cytosar U,beta Ara C
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D006562 Herpes Zoster An acute infectious, usually self-limited, disease believed to represent activation of latent varicella-zoster virus (HERPESVIRUS 3, HUMAN) in those who have been rendered partially immune after a previous attack of CHICKENPOX. It involves the SENSORY GANGLIA and their areas of innervation and is characterized by severe neuralgic pain along the distribution of the affected nerve and crops of clustered vesicles over the area. (From Dorland, 27th ed) Shingles,Zona,Zoster

Related Publications

V M de Moraes, and V A Neto, and J Pasternak, and G W Oselka, and G C Levi
November 1973, Deutsche medizinische Wochenschrift (1946),
V M de Moraes, and V A Neto, and J Pasternak, and G W Oselka, and G C Levi
November 1977, Klinische Monatsblatter fur Augenheilkunde,
V M de Moraes, and V A Neto, and J Pasternak, and G W Oselka, and G C Levi
January 1973, Archives of ophthalmology (Chicago, Ill. : 1960),
V M de Moraes, and V A Neto, and J Pasternak, and G W Oselka, and G C Levi
November 1973, The Medical journal of Australia,
V M de Moraes, and V A Neto, and J Pasternak, and G W Oselka, and G C Levi
July 1975, Archives of dermatology,
V M de Moraes, and V A Neto, and J Pasternak, and G W Oselka, and G C Levi
January 1976, British medical journal,
V M de Moraes, and V A Neto, and J Pasternak, and G W Oselka, and G C Levi
March 1979, Klinika oczna,
V M de Moraes, and V A Neto, and J Pasternak, and G W Oselka, and G C Levi
March 1977, Deutsche medizinische Wochenschrift (1946),
V M de Moraes, and V A Neto, and J Pasternak, and G W Oselka, and G C Levi
January 1997, Medicinski pregled,
V M de Moraes, and V A Neto, and J Pasternak, and G W Oselka, and G C Levi
December 1983, Canadian Medical Association journal,
Copied contents to your clipboard!